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Introduction
Ketanserin is a selective antagonist of serotonin (5-hydroxytryptamine, 5-HT) at 5-HT2 receptors which is currently being evaluated for the treatment of hypertension,1 2 intermittent claudication3'4 and Raynaud's phenomenon. 5 It prolongs the corrected QT interval on the electrocardiogram (ECG) of healthy subjects.6 Drug-induced QT prolongation may predispose to serious ventricular arrhythmias, particularly the polymorphous form of ventricular tachycardia known as torsade de pointes. 7 We have examined the influence of ketanserin on the QT interval of 81 patients with hypertension or intermittent claudication who participated in three studies. Our aims were to confirm that ketanserin prolonged the QT interval; to examine the timecourse of the phenomenon after single doses and during chronic treatment; to determine whether the effect was dose-dependent; and to explore the relation of QT prolongation to plasma drug concentration and other variables such as body weight.
Materials and methods
All patients gave written informed consent to the studies which were approved by the hospital ethics committee. The protocols are described in the results section for clarity of presentation. No patient was taking any drug which causes pronounced prolongation of the QT interval, and drug therapy other than ketanserin or placebo was held constant throughout all three studies. Patients with important hepatic or renal dysfunction were excluded.
In each patient the QT interval was measured from a single lead (usually lead II), recorded at a paper speed of 50mm/s, as the time from the first deflection of the QRS complex to the point where a tangent drawn along the descending limb of the T wave crossed the isoelectric line. U waves were excluded. All measurements were made by a single observer who was unaware of the treatment taken or sequence of traces, to avoid bias. The QT interval was corrected for heart rate using Bazett's correction.8 Because of controversy over the most appropriate method of correcting the QT interval for heart rate9 a further method of analysis was used in Study 2, the largest of the three studies. The relations between the uncorrected QT interval and the R-R interval were compared in ketanserin and placebo-treated patients by linear regression. The slopes of the regression lines were constrained to be parallel'0 and the intercepts for ketanserin and placebo treatment were compared. A significant difference between the intercepts in this analysis indicates a difference in QT interval which is independent of heart rate and any correction factor.
Blood was taken for assay of plasma concentrations of ketanserin and its major metabolite ketanserinol, at the time of each QT interval measurement. Samples were stored at -20'C prior to assay by high performance liquid chromatography with fluorescence detection. R 46594 (Janssen Pharmaceutica, Beerse) was used as an internal standard. The limit of detection of the assay was 1 ng/ml and the coefficients of variation were 5.0% (ketanserin) and 2.7% (ketanserinol) at a concentration of 200 ng/ml. Serum potassium and calcium concentrations were measured before treatment and at the final assessment. Serum calcium values were corrected for serum albumin concentration.
Histograms and normal probability plots suggested that the data were normally distributed. Values for plasma ketanserin and ketanserinol concentrations were log-transformed before analysis. The statistical methods used were paired t-tests, analysis of variance and multiple linear regression. Figure 3 ). QTC interval prolongation was observed particularly in women, who weighed less than men. After adjustment for weight, sex and age ketanserin still prolonged the QTC interval significantly compared to placebo, by a mean of 15ms (95% CI+5, +25ms, P<0.01).
Results

Study
The increase in QTC interval was significantly related to the dose of ketanserin when corrected for body weight (r=0.63, P<0.01, Figure 4 ). There was no significant relation between plasma drug or metabolite concentrations and QTc prolongation.
Serum potassium and calcium concentrations did not alter during the study and were not related to changes in the QTC interval.
The relation of uncorrected QT interval to R-R interval was examined by linear regression to ensure that the findings described above were independent of Bazett's correction (see Methods). There was a significant difference of 22 ms (P <0.02) between the intercepts for ketanserin and placebo ( Figure 5 ), indicating that ketanserin prolonged the QT interval by 22 ms independent of heart rate.
Electrocardiograms with QTC prolongation frequently showed T wave flattening, and in some cases the T wave was bifid, independent of the U wave ( Figure 6 ). There was no change in QRS duration and thus QT interval prolongation resulted from lengthening of the JT segment.
Comment Ketanserin treatment prolonged the QTC interval significantly, by a mean of 14 increase is likely to be doubled 4 hours after dosing, as shown in Study 1. QTv prolongation was related to body weight, and the regression equation predicts substantial prolongation (30ms or more) in those weighing 50-60kg, but no increase in those weighing 90-100kg. Lengthening of the QTr interval with ketanserin was dose-dependent. A dose of 1.6mg/kg/day increased the QTC interval by an average of 30ms 14 hours after dosing, whereas a dose of 0.6 mg/kg/day caused no change.
Increases in the QTC were unrelated to concentrations of ketanserin, ketanserinol, potassium or calcium in blood.
Study 3
Protocol Twenty-one patients with intermittent claudication (14 men, 7 women, mean age 59.8 years) were randomly allocated to ketanserin, mean dose 167 mg/day or placebo, each given for 3 months. The QTC interval was measured 2-4 hours after dosing.
Results The two treatment groups were well- and changes in T wave morphology similar to those reported with amiodarone.1' Ketanserin-induced prolongation of the QTC was observed when the drug was prescribed as monotherapy, and when it was added to thiazide diuretic or f-blocker therapy. It was not related to serum potassium or calcium concentrations. Extreme QT, prolongation, up to 80ms, was observed at high doses of ketanserin.
Drugs which prolong the QT interval substantially may predispose patients to serious cardiac arrhythmias, particularly the form of ventricular tachycardia known as torsade de pointes.7 Ketanserin may be introduced for the treatment of hypertension in the near future, and the dose proposed is 40-80 mg/day. The results presented here suggest that a dose of 80mg/day would prolong the QTC interval by an average of 30 ms in a patient weighing 50 kg when it is measured 14 hours after dosing. In such a patient the expected increase four hours after dosing would be around 60 ms. We have not observed arrhythmias during ketanserin treatment, but as far as we are aware all drugs which prolong the QT interval to this extent have been associated with serious arrhythmias. Four cases of ventricular arrhythmias during treatment with ketanserin have already been reported. 13' 14 If ketanserin does become available for use in hypertension it will be prescribed to patients with a high prevalence of heart disease, and it may be prescribed with other drugs which prolong the QT interval. The risk of arrhythmias needs to be quantitated in a large population of patients before it comes into general use. Meanwhile, patients treated with ketanserin should have their QT interval monitored regularly, and should not be treated with other drugs known to prolong the QT interval. 
